Free Trial
→ June 12: $100 Turns Into $100,000? (From Brownstone Research) (Ad)tc pixel Free ZVSA Stock Alerts

ZyVersa Therapeutics (ZVSA) Competitors

ZyVersa Therapeutics logo
$0.18 0.00 (0.00%)
As of 05/22/2026 02:38 PM Eastern
Compare

ZVSA vs. APVO, CAPS, CUPR, RVPH, and FBLG

Should you buy ZyVersa Therapeutics stock or one of its competitors? MarketBeat compares ZyVersa Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ZyVersa Therapeutics include Aptevo Therapeutics (APVO), Capstone Therapeutics (CAPS), Cuprina Holdings (Cayman) (CUPR), Reviva Pharmaceuticals (RVPH), and FibroBiologics (FBLG). These companies are all part of the "pharmaceutical products" industry.

How does ZyVersa Therapeutics compare to Aptevo Therapeutics?

ZyVersa Therapeutics (NASDAQ:ZVSA) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

ZyVersa Therapeutics' return on equity of -109.54% beat Aptevo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ZyVersa TherapeuticsN/A -109.54% -43.95%
Aptevo Therapeutics N/A -198.50%-117.06%

In the previous week, Aptevo Therapeutics had 1 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 1 mentions for Aptevo Therapeutics and 0 mentions for ZyVersa Therapeutics. Aptevo Therapeutics' average media sentiment score of 0.50 beat ZyVersa Therapeutics' score of 0.00 indicating that Aptevo Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
ZyVersa Therapeutics Neutral
Aptevo Therapeutics Positive

3.9% of ZyVersa Therapeutics shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 0.2% of ZyVersa Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Aptevo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ZyVersa Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aptevo Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.33

ZyVersa Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market.

ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ZyVersa TherapeuticsN/AN/A-$9.41M-$0.83N/A
Aptevo TherapeuticsN/AN/A-$25.97M-$197.60N/A

Summary

Aptevo Therapeutics beats ZyVersa Therapeutics on 7 of the 12 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to Capstone Therapeutics?

Capstone Therapeutics (NASDAQ:CAPS) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

2.6% of Capstone Therapeutics shares are owned by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 39.3% of Capstone Therapeutics shares are owned by insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ZyVersa Therapeutics has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -41.26%. ZyVersa Therapeutics' return on equity of -109.54% beat Capstone Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Capstone Therapeutics-41.26% -114.15% -39.74%
ZyVersa Therapeutics N/A -109.54%-43.95%

In the previous week, Capstone Therapeutics had 4 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 4 mentions for Capstone Therapeutics and 0 mentions for ZyVersa Therapeutics. ZyVersa Therapeutics' average media sentiment score of 0.00 beat Capstone Therapeutics' score of -0.75 indicating that ZyVersa Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Capstone Therapeutics Negative
ZyVersa Therapeutics Neutral

ZyVersa Therapeutics has lower revenue, but higher earnings than Capstone Therapeutics. ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Capstone Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capstone Therapeutics$48.11M0.10-$21.23M-$3.37N/A
ZyVersa TherapeuticsN/AN/A-$9.41M-$0.83N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Capstone Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ZyVersa Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Capstone Therapeutics has a beta of -1.52, suggesting that its stock price is 252% less volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market.

Summary

ZyVersa Therapeutics beats Capstone Therapeutics on 7 of the 13 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to Cuprina Holdings (Cayman)?

Cuprina Holdings (Cayman) (NASDAQ:CUPR) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 0.2% of ZyVersa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cuprina Holdings (Cayman)'s return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cuprina Holdings (Cayman)N/A N/A N/A
ZyVersa Therapeutics N/A -109.54%-43.95%

In the previous week, Cuprina Holdings (Cayman) had 2 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 2 mentions for Cuprina Holdings (Cayman) and 0 mentions for ZyVersa Therapeutics. ZyVersa Therapeutics' average media sentiment score of 0.00 beat Cuprina Holdings (Cayman)'s score of -0.19 indicating that ZyVersa Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Cuprina Holdings (Cayman) Neutral
ZyVersa Therapeutics Neutral

Cuprina Holdings (Cayman) has higher revenue and earnings than ZyVersa Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cuprina Holdings (Cayman)$40K141.70-$3.63MN/AN/A
ZyVersa TherapeuticsN/AN/A-$9.41M-$0.83N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cuprina Holdings (Cayman)
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ZyVersa Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Cuprina Holdings (Cayman) beats ZyVersa Therapeutics on 6 of the 9 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to Reviva Pharmaceuticals?

Reviva Pharmaceuticals (NASDAQ:RVPH) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Reviva Pharmaceuticals has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Reviva PharmaceuticalsN/AN/A-$19.86M-$4.06N/A
ZyVersa TherapeuticsN/AN/A-$9.41M-$0.83N/A

ZyVersa Therapeutics' return on equity of -109.54% beat Reviva Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Reviva PharmaceuticalsN/A -391.58% -119.08%
ZyVersa Therapeutics N/A -109.54%-43.95%

In the previous week, Reviva Pharmaceuticals had 1 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 1 mentions for Reviva Pharmaceuticals and 0 mentions for ZyVersa Therapeutics. Reviva Pharmaceuticals' average media sentiment score of 0.00 equaled ZyVersa Therapeutics'average media sentiment score.

Company Overall Sentiment
Reviva Pharmaceuticals Neutral
ZyVersa Therapeutics Neutral

63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are held by institutional investors. 8.9% of Reviva Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Reviva Pharmaceuticals currently has a consensus price target of $66.67, indicating a potential upside of 16,042.05%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Reviva Pharmaceuticals is more favorable than ZyVersa Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Reviva Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50
ZyVersa Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Reviva Pharmaceuticals beats ZyVersa Therapeutics on 7 of the 12 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to FibroBiologics?

FibroBiologics (NASDAQ:FBLG) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 9.3% of FibroBiologics shares are owned by company insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, FibroBiologics had 1 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 1 mentions for FibroBiologics and 0 mentions for ZyVersa Therapeutics. FibroBiologics' average media sentiment score of 0.00 equaled ZyVersa Therapeutics'average media sentiment score.

Company Overall Sentiment
FibroBiologics Neutral
ZyVersa Therapeutics Neutral

ZyVersa Therapeutics' return on equity of -109.54% beat FibroBiologics' return on equity.

Company Net Margins Return on Equity Return on Assets
FibroBiologicsN/A -767.07% -195.56%
ZyVersa Therapeutics N/A -109.54%-43.95%

ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FibroBiologicsN/AN/A-$18.65M-$6.93N/A
ZyVersa TherapeuticsN/AN/A-$9.41M-$0.83N/A

FibroBiologics has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market.

FibroBiologics presently has a consensus target price of $74.00, indicating a potential upside of 6,947.62%. Given FibroBiologics' stronger consensus rating and higher probable upside, equities analysts plainly believe FibroBiologics is more favorable than ZyVersa Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FibroBiologics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
ZyVersa Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

FibroBiologics beats ZyVersa Therapeutics on 7 of the 12 factors compared between the two stocks.

Get ZyVersa Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZVSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZVSA vs. The Competition

Export
MetricZyVersa TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.43M$3.37B$6.46B$12.34B
Dividend YieldN/A2.26%2.76%5.28%
P/E Ratio-0.2218.7421.0025.66
Price / SalesN/A323.98562.1886.31
Price / CashN/A125.1743.4956.67
Price / Book0.057.0910.417.14
Net Income-$9.41M$24.45M$3.57B$335.98M
7 Day Performance-2.70%6.38%6.40%4.11%
1 Month Performance-14.29%2.43%3.54%2.52%
1 Year Performance-66.67%62.98%34.14%35.04%

ZyVersa Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZVSA
ZyVersa Therapeutics
N/A$0.18
flat		N/A-66.7%$1.43MN/AN/A2
APVO
Aptevo Therapeutics
1.3462 of 5 stars		$5.04
+10.8%		N/A-95.0%$5.68MN/AN/A50
CAPS
Capstone Therapeutics
0.5675 of 5 stars		$0.33
-14.0%		N/A-80.8%$5.56M$48.11MN/A38
CUPR
Cuprina Holdings (Cayman)
1.2163 of 5 stars		$0.28
+5.4%		N/AN/A$5.56M$40KN/A14
RVPH
Reviva Pharmaceuticals
2.2757 of 5 stars		$0.42
+7.2%		$66.67
+15,795.7%		-98.0%$5.50MN/AN/A5

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ZVSA) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Opportunity Forming in a U.S. Supply-Chain Weak Spot?
America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...
i2i Marketing Group, LLC | Sponsoredtc pixel